HormoneSensitiveProstateCancer Archives

News
Regulatory & Policy

Bayer’s Nubeqa Receives Expanded Approval in India for mHSPC with ADT

Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030.&nbsp...

Ridhi Rastogi

February 26, 2026

Browsing Tag: HormoneSensitiveProstateCancer

Bayer’s Nubeqa Receives Expanded Approval in India for mHSPC with ADT

Featured Posts

AstraZeneca’s Enhertu Gets New Breast Cancer Indication in India

Top 10 Indian BioPharma Companies of 2026

Bristol Myers Squibb Launches Relopduo for Advanced Melanoma in India